Revance Therapeutics, Inc. (RVNC)
Feb 6, 2025 = RVNC was delisted (reason: acquired by Crown Laboratories)
3.650
0.00 (0.00%)
Inactive · Last trade price
on Feb 6, 2025
Revance Therapeutics Analyst Ratings
Total Analysts
9
Consensus Rating
Hold
Price Target
$7.78
Upside
+113.15%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 17, 2025 |
| Barclays | Barclays | Hold Maintains $7 → $3 | Hold | Maintains | $7 → $3 | -17.81% | Dec 23, 2024 |
| Mizuho | Mizuho | Hold Maintains $6.66 → $3.1 | Hold | Maintains | $6.66 → $3.1 | -15.07% | Dec 10, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $6.6 | Hold | Reiterates | $6.6 | +80.82% | Nov 8, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 28, 2024 |
| Barclays | Barclays | Buy → Hold Downgrades $10 → $7 | Buy → Hold | Downgrades | $10 → $7 | +91.78% | Sep 13, 2024 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 13, 2024 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 12, 2024 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 12, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $6 | Buy | Maintains | $11 → $6 | +64.38% | Aug 9, 2024 |
| Stifel | Stifel | Strong Buy Maintains $24 → $20 | Strong Buy | Maintains | $24 → $20 | +447.95% | Aug 9, 2024 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +228.77% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +201.37% | May 13, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $9 → $8 | Hold | Maintains | $9 → $8 | +119.18% | May 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $20 → $11 | Buy | Reiterates | $20 → $11 | +201.37% | May 10, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.